Net Cash Provided by (Used in) Operating Activities |
-200K |
USD |
-61.8% |
Q2 2024 |
Q1 2025 |
Net Cash Provided by (Used in) Financing Activities |
-37.8M |
USD |
-5505% |
Q2 2024 |
Q1 2025 |
Net Cash Provided by (Used in) Investing Activities |
38.4M |
USD |
|
Q2 2024 |
Q1 2025 |
Common Stock, Shares Authorized |
15M |
shares |
0% |
Q2 2024 |
Q1 2025 |
Common Stock, Shares, Issued |
1.85M |
shares |
0% |
Q2 2024 |
Q1 2025 |
Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q2 2024 |
Q1 2025 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
445K |
USD |
+67.3% |
Q2 2024 |
Q1 2025 |
Deferred Tax Assets, Valuation Allowance |
480K |
USD |
|
Q2 2024 |
Q1 2025 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0.21 |
pure |
0% |
Q2 2024 |
Q1 2025 |
Deferred Tax Assets, Gross |
436K |
USD |
+94.5% |
Q2 2024 |
Q1 2025 |
Deferred Income Tax Expense (Benefit) |
-6.75K |
USD |
-261% |
Q2 2024 |
Q1 2025 |
Deferred Tax Assets, Operating Loss Carryforwards |
80.1K |
USD |
|
Q3 2022 |
Q2 2022 |
Deferred Federal Income Tax Expense (Benefit) |
-7.96K |
USD |
-261% |
Q2 2024 |
Q1 2025 |
Unrecognized Tax Benefits |
0 |
USD |
-100% |
Q1 2023 |
FY 2023 |
Additional Paid in Capital |
795K |
USD |
|
Q4 2022 |
Q3 2023 |
Current Federal Tax Expense (Benefit) |
621K |
USD |
+5.19% |
Q2 2024 |
Q1 2025 |
Deferred Tax Assets, Net of Valuation Allowance |
80.1K |
USD |
|
Q3 2022 |
Q2 2022 |
Interest Expense |
50K |
USD |
|
Q2 2024 |
Q1 2025 |